Ocular Therapeutix
OCUL
149 hedge funds and large institutions have $685M invested in Ocular Therapeutix in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 59 increasing their positions, 35 reducing their positions, and 28 closing their positions.
120% more call options, than puts
Call options by funds: $24.5M | Put options by funds: $11.1M
69% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 35
1.29% more ownership
Funds ownership: 62.11% → 63.4% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3% less funds holding
Funds holding: 154 → 149 (-5)
12% less capital invested
Capital invested by funds: $774M → $685M (-$89.5M)
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$27M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.4M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$8.53M |
| 4 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$8.22M |
| 5 |
Renaissance Technologies
New York
|
+$4.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$23.4M |
| 2 |
BlackRock
New York
|
-$13.5M |
| 3 |
CM
Castleark Management
Chicago,
Illinois
|
-$7.97M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$7.04M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.14M |
OCUL Hedge Fund Activity: Q2 2021 in Review
149 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2021, worth a combined $685M — down 12% from $774M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of OCUL and 23 opened new positions — a net loss of 5 holders — while 35 trimmed existing stakes and 59 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $27M. The largest seller was Victory Capital Management, cutting an estimated $23.4M.
- 149 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2021, down from 154 in Q1 2021.
- Funds reported $685M of Ocular Therapeutix stock for Q2 2021, down 12% quarter-over-quarter.
- 23 funds opened new Ocular Therapeutix positions in Q2 2021 and 28 closed out, a net change of -5 holders.
- The largest Ocular Therapeutix buyer in Q2 2021 was Rubric Capital Management (New York), an estimated $27M added.
- The largest Ocular Therapeutix seller in Q2 2021 was Victory Capital Management, an estimated $23.4M sold.
Based on aggregated 13F filings for Q2 2021.